Trelegy Ellipta vs Tezspire
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Trelegy Ellipta | US Tezspire | |
|---|---|---|
| Generic name | fluticasone/umeclidinium/vilanterol | tezepelumab |
| Drug class | Inhaled Corticosteroid + LAMA + LABA | TSLP Blocker (Biologic) |
| Treats | COPD, asthma | Severe asthma |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | Amgen/AstraZeneca |
| Year approved | 2017 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $200M | $70M |
| Common side effects | Thrush, Respiratory infections, Headache, Cough | Sore throat, Joint pain, Back pain, Injection site reactions |
Trelegy Ellipta
Frequently asked questions
Is Trelegy Ellipta or Tezspire better?
Neither is universally "better." Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) and Tezspire (tezepelumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Trelegy Ellipta and Tezspire?
Trelegy Ellipta is a Inhaled Corticosteroid + LAMA + LABA made by GSK, while Tezspire is a TSLP Blocker (Biologic) made by Amgen/AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Trelegy Ellipta has the larger estimated TV advertising budget of the two.